About CellBion
CellBion is a company based in Seoul (South Korea) founded in 2010. CellBion operates in a competitive market with competitors including ARTMS, NorthStar Medical Radioisotopes, Niowave, Nanovista and Ground Fluor Pharmaceuticals, among others.
- Headquarter Seoul, South Korea
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Cellbion Co., Ltd
-
Annual Revenue
$1.55 M (USD)55.64as on Dec 31, 2024
-
Net Profit
-$4.93 M (USD)-100.01as on Dec 31, 2024
-
EBITDA
-$4.41 M (USD)-47.14as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of CellBion
CellBion is a publicly listed company on the KRX with ticker symbol 308430 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of CellBion
Detailed funding history for CellBion
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CellBion
Investment portfolio details for CellBion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CellBion
Detailed financials for CellBion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cellbion Comparisons
Peer comparison for CellBion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CellBion
CellBion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ARTMS, NorthStar Medical Radioisotopes, Niowave, Nanovista and Ground Fluor Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Radioisotope technologies and services are developed and provided by ARTMS.
|
|
| Locked | Locked | Locked |
Provider of sourcing, purification, and separation technologies for the Nuclear Medicine market
|
|
| Locked | Locked | Locked |
Devices and radioisotopes for nuclear imaging are provided by Niowave.
|
|
| Locked | Locked | Locked |
Multimodal visualization agents are developed for image-guided interventions.
|
|
| Locked | Locked | Locked |
Proprietary chemistry for pharmaceutical synthesis is developed by the company.
|
Detailed competitors of CellBion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cellbion
Complete news archive for CellBion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CellBion
CellBion was founded in 2010.
CellBion is headquartered in Seoul, South Korea.
Kweon Kim is the current CEO of CellBion.
Annual revenue of CellBion is $1.55M as on Dec 31, 2024.
CellBion was founded in 2010 in Seoul, South Korea, within the biotechnology sector. Radioisotope probes for imaging are produced, focusing on diagnostic agents for PET-CT, PET-MRI, and blood vessel imaging in atherosclerosis patients. Therapeutic applications are also developed, including treatments for cardio and cerebrovascular conditions. The technology is applied additionally in the food industry for various uses.
CellBion's top competitors include ARTMS, NorthStar Medical Radioisotopes and Niowave.
Yes, CellBion is publicly traded on KRX under the ticker symbol 308430.
The ticker symbol of CellBion is 308430 on KRX.